MedPath

Evaluation of the Effectiveness, Safety, and Cost of a Smart Hospital System for Patients With Chronic Obstructive Pulmonary Disease

Not Applicable
Recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Behavioral: Immediate application of the Smart Homespital system
Behavioral: Delayed application of the Smart Homespital system after 3 months
Registration Number
NCT06601777
Lead Sponsor
Yonsei University
Brief Summary

This study aims to analyze the effectiveness/safety/cost of the Smart Homespital system that provides a service that allows patients with Chronic Obstructive Pulmonary Disease to easily access and use biosignals generated using biosignal collection medical equipment at home.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
198
Inclusion Criteria

Patients diagnosed with COPD who meet the following pulmonary function test results:

  1. Pre FEV1 < 80% **or**
  2. Pre FVC < 80% **or**
  3. DLCO < 60%
Exclusion Criteria
  1. Patients who do not agree to participate in the study.
  2. Patients who fail to use the medical device equipment.
  3. Patients where tracking during the study period is expected to be impossible.
  4. Patients who have difficulty communicating verbally.
  5. Patients who are bedridden or unable to exercise at all due to severe cardiorespiratory dysfunction.
  6. Patients receiving hospital-centered rehabilitation treatment during the study period.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
intervention groupImmediate application of the Smart Homespital systemThe Smart Homespital system can be applied for the first 3 months (12 weeks), and then the primary and secondary variables will be evaluated at 3, 6, 9months.
attention-waitlist control groupDelayed application of the Smart Homespital system after 3 monthsThe waiting list-control group will receive general medical services for the first 3 months and will receive the Smart Homespital system for 3-6 months. Primary and secondary variables will be evaluated between 3, 6, and 9 months.
Primary Outcome Measures
NameTimeMethod
Respiratory symptom questionnaireAfter applying the Smart Homespital system(12weaks)

For survey scores, success is defined as an increase in the respective defined MCID(the minimal clinically important difference) rises the baseline.

1) Chronic respiratory questionnaire (CRQ)

* Success: 4 points or more 2.)Modified Medical Research Council dyspnea scale (mMRC)

* Success: 1points or more 3) EQ-5D

* Success: 1 points or more

Secondary Outcome Measures
NameTimeMethod
Depression QuestionnaireSurvey every 2 weeks during the 12-week Homespital system application, then at 3, 6, and 9 months after the start of the study.

K-CESD-R : Survey every 2 weeks during the 12-week Homespital system application, then at 3, 6, and 9 months after the start of the study.

* Success Criteria: Achieving 4 points or more.

* Success: 4 points or more

Service satisfaction evaluationAfter 12 weeks of applying the Smart Homespital system.

CSQ-8: After 12 weeks of applying the Smart Homespital system.

- Success Criteria: Achieving 4 points or more.

safetyMeasured after the study ends (9 months later).

* Number of hospital visits directly related to the Smart Home Hospital Program

* Success Criteria: Less than 2 hospital visits related to the Smart Homespital program.

cost assessmentAfter study ends (9 months later)

Criteria: Comparison of average hospital respiratory rehabilitation treatment costs with the Smart Homespital program's costs.

6 minute walking testAt 3, 6, and 9 months.

- Success Criteria: More than a 10% increase over the baseline.

pulmonary function testAt 3, 6, and 9 months.

Success Criteria: Increase in FVC, FEV1, or DLCO by more than 10% at the time of registration.

system complianceDuring the 12-week period of applying the Homespital system.

Criteria: Maintaining a minimum of 5,000 steps/day during the 12-week period of applying the Homespital system.

Trial Locations

Locations (1)

Severance Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath